K2P Potassium Channel Activators for Morphine-Sparing Analgesia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management with morphine is hindered by significant constipating and respiratory depressant effects, limiting its therapeutic benefit and increasing the risk of adverse reactions, particularly in elderly patients and those with cancer.
Innovation Solution
Targeting K2P potassium channels, specifically TREK-1 and TRAAK, to develop analgesics that activate these channels without causing constipation or respiratory depression, thereby isolating compounds that offer analgesic effects without the undesirable side effects of morphine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If morphine is used for pain relief, then analgesic effect is improved, but constipating and respiratory depressant effects worsen
Solution Approach 1:
The patent extracts and isolates the beneficial analgesic effect from the harmful constipating and respiratory depressant effects by identifying a specific downstream mechanism (K2P potassium channel activation) that is responsible only for pain relief. By targeting this specific channel rather than the broad opioid receptor system, the invention separates the desired therapeutic effect from the unwanted side effects.
Solution Approach 2:
The patent introduces an intermediary mechanism - the K2P potassium channel - as a mediator between the analgesic action and the patient's physiological system. By activating this intermediate channel rather than directly targeting opioid receptors, the invention achieves pain relief while avoiding the direct activation of pathways that lead to constipation and respiratory depression.
2Reliability
If opioid analgesics are prescribed for chronic pain management, then pain relief is improved, but adverse effects increase
Solution Approach 1:
The patent extracts the analgesic function from the harmful adverse effects by identifying a specific molecular target (K2P potassium channel) that mediates only the beneficial pain-relieving action. This selective targeting removes the association between pain relief and adverse effects such as constipation, respiratory depression, and sedation.
Solution Approach 2:
The patent changes the molecular target parameter from broad opioid receptors to the specific K2P potassium channel. This parameter change in the site of action transforms the pharmacological profile, maintaining effective analgesia while eliminating the adverse effects associated with traditional opioid receptor activation.
3Reliability
If morphine is used in elderly patients, then analgesic effect is achieved, but risk of hallucinations and confusion increases
Solution Approach 1:
The patent uses the K2P potassium channel as an intermediary target that mediates analgesia without triggering the neurological pathways associated with hallucinations and confusion in elderly patients. This intermediate mechanism provides pain relief while bypassing the central nervous system effects that cause psychiatric side effects.
Solution Approach 2:
The patent changes the pharmacological target parameter from opioid receptors to K2P potassium channels, which fundamentally alters the side effect profile. This parameter change eliminates the risk of hallucinations and confusion while preserving the analgesic effect, making the treatment suitable for elderly patients.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for the identification and development of analgesics that provide effective pain relief without constipating or respiratory depressant effects, improving the benefit-to-risk ratio and reducing post-operative and chronic pain management challenges.
Implementation Method 1
K2P potassium channels, and more particularly of TREK-1 and TRAAK, in the analgesic effect of morphine
Implementation Method 2
The TREK-1 and TRAAK channels are therefore necessary for the analgesic action
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention relates to pain treatment and prevention. Specifically, the present invention shows the involvement of K2P potassium channels in the antalgic effect of morphine. The present invention therefore provides a screening method for identifying antalgics.